Rachna Khosla - May 2, 2023 Form 4 Insider Report for AMGEN INC (AMGN)

Role
SVP, Business Development
Signature
/s/ Rachna Khosla
Stock symbol
AMGN
Transactions as of
May 2, 2023
Transactions value $
-$13,450
Form type
4
Date filed
5/4/2023, 08:28 PM
Previous filing
May 2, 2023
Next filing
May 9, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AMGN Common Stock Award $0 +593 +8.37% $0.00 7.68K May 2, 2023 Direct F1
transaction AMGN Common Stock Tax liability -$13.5K -57 -0.74% $235.97 7.62K May 3, 2023 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AMGN Nqso (Right to Buy) Award $0 +5.02K $0.00 5.02K May 2, 2023 Common Stock 5.02K $235.97 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units (RSUs) were granted pursuant to the Amgen Inc. 2009 Amended and Restated Equity Incentive Plan and vest in three annual installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.
F2 These shares include the following RSUs granted under the Company's equity plans: 201 RSUs which will vest in installments of 99 on 5/5/2023 and 102 on 5/5/2024; 252 RSUs which will vest in installments of 124 on 4/30/2024 and 128 on 4/30/2025; 1,169 RSUs which will vest in installments of 385 on 11/5/2023, 386 on 11/5/2024 and 398 on 11/5/2025; 468 RSUs which will vest on 11/5/2023; 606 RSUs which will vest in installments of 199 on 5/2/2024, 200 on 5/2/2025, and 207 on 5/2/2026; and 593 RSUs which will vest in in installments of 195 on 5/2/2025, 196 on 5/2/2026 and one installment of 202 on 5/2/2027. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
F3 These shares include 137 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
F4 These non-qualified stock options are exercisable in three installments of 33%, 33% and 34% on 5/2/2025, 5/2/2026 and 5/2/2027, respectively.